EA201791518A1 - Способы лечения заболеваний сетчатки - Google Patents

Способы лечения заболеваний сетчатки

Info

Publication number
EA201791518A1
EA201791518A1 EA201791518A EA201791518A EA201791518A1 EA 201791518 A1 EA201791518 A1 EA 201791518A1 EA 201791518 A EA201791518 A EA 201791518A EA 201791518 A EA201791518 A EA 201791518A EA 201791518 A1 EA201791518 A1 EA 201791518A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
cells
retail
methods
treat diseases
Prior art date
Application number
EA201791518A
Other languages
English (en)
Russian (ru)
Inventor
Эйяль Банин
Бенджамин Этан Рубинофф
Оснат Бохана-Каштан
Нир Нетзер
Чарльз Шерард Ирвинг
Original Assignee
Селл Кьюр Нейросайансес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56284392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Селл Кьюр Нейросайансес Лтд. filed Critical Селл Кьюр Нейросайансес Лтд.
Publication of EA201791518A1 publication Critical patent/EA201791518A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00727—Apparatus for retinal reattachment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201791518A 2014-12-30 2015-04-30 Способы лечения заболеваний сетчатки EA201791518A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462097753P 2014-12-30 2014-12-30
US201562116980P 2015-02-17 2015-02-17
US201562116972P 2015-02-17 2015-02-17
PCT/IL2015/050456 WO2016108219A1 (en) 2014-12-30 2015-04-30 Methods of treating retinal diseases

Publications (1)

Publication Number Publication Date
EA201791518A1 true EA201791518A1 (ru) 2017-10-31

Family

ID=56284392

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791518A EA201791518A1 (ru) 2014-12-30 2015-04-30 Способы лечения заболеваний сетчатки

Country Status (18)

Country Link
US (2) US20180008458A1 (https=)
EP (1) EP3240612B1 (https=)
JP (4) JP2018501281A (https=)
KR (2) KR102359257B1 (https=)
CN (3) CN114533761A (https=)
AU (3) AU2015373111B2 (https=)
BR (1) BR112017014332A2 (https=)
CA (2) CA3175175A1 (https=)
DK (1) DK3240612T3 (https=)
EA (1) EA201791518A1 (https=)
ES (1) ES2843626T3 (https=)
HK (1) HK1246179A1 (https=)
IL (1) IL253244B2 (https=)
MX (1) MX2017008818A (https=)
PH (1) PH12017501217A1 (https=)
SG (1) SG11201705378RA (https=)
WO (1) WO2016108219A1 (https=)
ZA (1) ZA201704359B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281453B (en) 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
EP3916085A1 (en) 2014-12-30 2021-12-01 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
CA2972575A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
EP3240612B1 (en) 2014-12-30 2020-12-23 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
WO2017017686A1 (en) 2015-07-29 2017-02-02 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
US11066642B2 (en) 2015-08-05 2021-07-20 Cell Cure Neurosciences Ltd Preparation of retinal pigment epithelium cells
EP3331995A1 (en) * 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
WO2018170494A1 (en) * 2017-03-16 2018-09-20 Bio Time, Inc. Methods for measuring therapeutic effects of retinal disease therapies
JP2020530839A (ja) 2017-07-31 2020-10-29 バイオタイム インコーポレイテッド 疾患または外傷性損傷を原因とする視覚喪失を回復させるまたは予防するための組成物および方法
WO2019130061A2 (en) 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
JP2021521792A (ja) 2018-04-20 2021-08-30 フジフィルム セルラー ダイナミクス，インコーポレイテッド 眼球細胞の分化方法及びその使用
CN108795864B (zh) * 2018-05-24 2021-08-24 中山大学中山眼科中心 一种利用人诱导多能干细胞获得富含视锥及视杆细胞的类视网膜组织的方法
US10264436B1 (en) * 2018-05-29 2019-04-16 Link Labs, Inc. BLE networking systems and methods providing central and peripheral role reversal with independent peripheral network connectivity
IL321380A (en) * 2018-08-31 2025-08-01 Univ Florida Adeno-associated viral vectors for the treatment of best disease
EP3969570A1 (en) * 2019-05-15 2022-03-23 Novo Nordisk A/S Methods for obtaining eye field progenitor cells from human pluripotent stem cells
CA3184790A1 (en) * 2020-05-25 2021-12-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
IL301042A (en) * 2020-09-03 2023-05-01 Curebiotec Gmbh Pigment epithelium-derived factor (pedf) for use in treatment of macular degeneration or choroidal neovascularisation
EP3964227A1 (en) * 2020-09-08 2022-03-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115137553A (zh) * 2022-07-11 2022-10-04 上海市同济医院 一种免造孔视网膜下液排出装置
CN115212233B (zh) * 2022-08-26 2024-05-28 北京市眼科研究所 用于治疗视网膜相关疾病的组合物、试剂盒及其应用
WO2024110625A1 (en) * 2022-11-24 2024-05-30 Universität Bern Cralbp based therapeutics for retinal disorders
KR102531735B1 (ko) * 2022-12-27 2023-05-12 주식회사 셀리코 초소형 자극기 및 이의 제조방법

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP2147094B2 (en) 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
DK2209888T3 (da) * 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
KR101025880B1 (ko) * 2008-10-23 2011-03-30 공희숙 성체 줄기세포를 이용한 인슐린 분비세포로의 분화 유도방법
IL281453B (en) * 2009-11-17 2022-07-01 Astellas Inst For Regenerative Medicine Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells
IL287381B2 (en) 2011-11-14 2024-04-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human rpe cells and uses thereof
US9850463B2 (en) * 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
US20150112282A1 (en) * 2012-04-09 2015-04-23 Industry-Academic Cooperation Foundation, Yonsei University Hollow microneedle and subretinal syringe for subretinal injection or extraction
EP2951290B1 (en) 2013-02-01 2017-11-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
MX2016007671A (es) * 2013-12-11 2016-10-14 Pfizer Ltd Metodo para producir celulas del epitelio pigmentario retiniano.
CA2972575A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Rpe cell populations and methods of generating same
EP3240612B1 (en) * 2014-12-30 2020-12-23 Cell Cure Neurosciences Ltd. Methods of treating retinal diseases
EP3916085A1 (en) 2014-12-30 2021-12-01 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
KR101982801B1 (ko) * 2015-10-28 2019-05-30 서울대학교 산학협력단 망막색소상피 분화 유도용 조성물

Also Published As

Publication number Publication date
KR102359257B1 (ko) 2022-02-07
AU2023255009A1 (en) 2023-11-16
IL253244B1 (en) 2023-05-01
CN114469998A (zh) 2022-05-13
JP2018501281A (ja) 2018-01-18
US20230028133A1 (en) 2023-01-26
JP2022125160A (ja) 2022-08-26
ES2843626T3 (es) 2021-07-19
CN107427534A (zh) 2017-12-01
JP2024023611A (ja) 2024-02-21
JP2020143137A (ja) 2020-09-10
KR20220020422A (ko) 2022-02-18
EP3240612B1 (en) 2020-12-23
PH12017501217A1 (en) 2018-01-29
CN114533761A (zh) 2022-05-27
IL253244B2 (en) 2023-09-01
DK3240612T3 (da) 2021-01-18
AU2021229196A1 (en) 2021-10-07
AU2015373111B2 (en) 2021-06-24
IL253244A0 (en) 2017-08-31
MX2017008818A (es) 2018-03-14
CA3175175A1 (en) 2016-07-07
US20180008458A1 (en) 2018-01-11
EP3240612A1 (en) 2017-11-08
EP3240612A4 (en) 2018-06-13
HK1246179A1 (zh) 2018-09-07
AU2015373111A1 (en) 2017-07-13
WO2016108219A1 (en) 2016-07-07
SG11201705378RA (en) 2017-08-30
KR102514912B1 (ko) 2023-03-27
ZA201704359B (en) 2018-08-29
KR20170120583A (ko) 2017-10-31
CA2972700A1 (en) 2016-07-07
BR112017014332A2 (pt) 2018-01-02

Similar Documents

Publication Publication Date Title
EA201791518A1 (ru) Способы лечения заболеваний сетчатки
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
PH12020551427A1 (en) Epinephrine spray formulations
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EP3468356A4 (en) GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF A DISEASE
WO2016210372A3 (en) Methods to treat neurological diseases
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
MX395523B (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
MX386702B (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
PH12017500392A1 (en) Medical treatments based on anamorelin
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201992389A1 (ru) Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение
SG10201811203TA (en) Protocols for treatment of major depressive disorder (mdd)
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
RU2017118158A (ru) Средство, стимулирующее продукцию тау-белка, и терапевтическое или профилактическое средство и терапевтическая или профилактическая пищевая композиция, предназначенные для лечения заболеваний, вызванных дефицитом тау-белка